Merck & Co. Inc. (MRK)

85.16
NYSE : Health Technology
Prev Close 83.97
Day Low/High 84.32 / 85.87
52 Wk Low/High 66.10 / 87.35
Avg Volume 9.57M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 214.99B
EPS 2.30
P/E Ratio 38.92
Div & Yield 2.20 (2.57%)

Latest News

FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment For Patients With Certain Types Of Endometrial Carcinoma

FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment For Patients With Certain Types Of Endometrial Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #5 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc is also a top tier analyst pick among the broader S&P 500 index components, claiming the #46 spot out of 500.

Got a Minute? Jim Cramer Breaks Down the Markets and Ticker Tape

Got a Minute? Jim Cramer Breaks Down the Markets and Ticker Tape

Jim Cramer's breaking down the ticker tape for investors.

FDA Accepts Merck's Biologics License Application (BLA) And Grants Priority Review For V920, The Company's Investigational Vaccine For Ebola Zaire Virus

FDA Accepts Merck's Biologics License Application (BLA) And Grants Priority Review For V920, The Company's Investigational Vaccine For Ebola Zaire Virus

Merck, known as MSD outside the United States and Canada, today announced that the U.

Merck Shares Could Trade Sideways Before Renewed Gains

Merck Shares Could Trade Sideways Before Renewed Gains

Let's visit with the charts and indicators to get another perspective.

Jim Cramer: How to Turn the Market Rotation Into an Opportunity

Jim Cramer: How to Turn the Market Rotation Into an Opportunity

Here's why this market rotation has Jim Cramer looking at Merck.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Tech Stocks Lag, Health Care Shakes Up and Apple's in TV

Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.

Merck Announces First Nine "Safer Childbirth Cities" Committed To Reducing Maternal Deaths And Narrowing Disparities In The US

Merck Announces First Nine "Safer Childbirth Cities" Committed To Reducing Maternal Deaths And Narrowing Disparities In The US

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities across the country to help end preventable maternal deaths.

Pooled Analysis Continues To Show Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy Improved Overall Survival Versus Chemotherapy Alone As First-Line Treatment For Patients With Advanced NSCLC Whose Tumors Do Not Express PD-L1

Pooled Analysis Continues To Show Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy Improved Overall Survival Versus Chemotherapy Alone As First-Line Treatment For Patients With Advanced NSCLC Whose Tumors Do Not Express PD-L1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that first-line treatment with KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy demonstrated improvements in overall survival (OS), progression-free...

Pivotal New Data From Merck's Broad Oncology Portfolio At ESMO 2019 Congress

Pivotal New Data From Merck's Broad Oncology Portfolio At ESMO 2019 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from its broad oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from...

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

In my opinion, MA is a good one, otherwise it would not be on my book.

Merck To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Merck Foundation Launches Five-Year Initiative To Reduce Disparities In HIV Care For Vulnerable And Underserved Southeastern US Communities

Merck Foundation Launches Five-Year Initiative To Reduce Disparities In HIV Care For Vulnerable And Underserved Southeastern US Communities

The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable and underserved Southeastern U.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma (RCC)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line...

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

These three names - GD, MRK, WMT - will either hit resistance or hurdle immediate pivot points in as traders (or bots) try to form a technical breakout.

Lannett to Be U.S. Distributor of Posaconazole Delayed-Release Tablets

Lannett to Be U.S. Distributor of Posaconazole Delayed-Release Tablets

The company will be the exclusive U.S. distributor of fungal disease medication Posaconazole delayed-release tablets.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Merck Highlights New Data From Leading Lung Cancer Clinical Development Program At The IASLC 2019 World Conference On Lung Cancer

Merck Highlights New Data From Leading Lung Cancer Clinical Development Program At The IASLC 2019 World Conference On Lung Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the company's leading clinical development program in lung cancer will be presented at the IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the...

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.

Moderna Stock Surges as FDA Fast Tracks Zika Vaccine

Moderna Stock Surges as FDA Fast Tracks Zika Vaccine

The biotech's investigational Zika vaccine is being evaluated in a Phase I study.

A Bottoms Up Look at the Dow Industrials

A Bottoms Up Look at the Dow Industrials

Stock by stock checking on how many were in uptrends.

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint As First-Line Maintenance Treatment With Bevacizumab For Advanced Ovarian Cancer

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint As First-Line Maintenance Treatment With Bevacizumab For Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 PAOLA-1 trial in women with advanced ovarian cancer.

Merck Announces Leadership Changes To Investor Relations Team

Merck Announces Leadership Changes To Investor Relations Team

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug.

Bullpen Update

These companies already posted strong earnings this season and are not economically sensitive.

LYNPARZA® (olaparib) Phase 3 PROfound Trial In HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

LYNPARZA® (olaparib) Phase 3 PROfound Trial In HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 PROfound trial of LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC) who have an homologous...

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.

FDA Approves New Monotherapy Indication For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves New Monotherapy Indication For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

TheStreet Quant Rating: A+ (Buy)